(Q39198154)

9 September 2017

Prospects for combining targeted and conventional cancer therapy with immunotherapy (English)

1 reference

9 September 2017

1 reference

Philip Gotwals

1

1 reference

9 September 2017

Scott Cameron

2

1 reference

9 September 2017

Daniela Cipolletta

3

1 reference

9 September 2017

Viviana Cremasco

4

1 reference

9 September 2017

Adam Crystal

5

1 reference

9 September 2017

Becker Hewes

6

1 reference

9 September 2017

Britta Mueller

7

1 reference

9 September 2017

Sonia Quaratino

8

1 reference

9 September 2017

Catherine Sabatos-Peyton

9

1 reference

9 September 2017

Lilli Petruzzelli

10

1 reference

9 September 2017

Jeffrey A Engelman

11

1 reference

9 September 2017

Glenn Dranoff

12

1 reference

9 September 2017

language of work or name

English

0 references

publication date

24 March 2017

1 reference

9 September 2017

Nature Reviews Cancer

1 reference

9 September 2017

17

1 reference

9 September 2017

5

1 reference

9 September 2017

286-301

1 reference

https://scigraph.springernature.com/pub.10.1038/nrc.2017.17

9 September 2017

0 references

cites work

Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Overall Survival and Durable Responses in Patients With BRAF V600-Mutant Metastatic Melanoma Receiving Dabrafenib Combined With Trametinib.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Dabrafenib plus trametinib in patients with previously treated BRAF(V600E)-mutant metastatic non-small cell lung cancer: an open-label, multicentre phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Erlotinib in previously treated non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Ceritinib in ALK-rearranged non-small-cell lung cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The future of immune checkpoint therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Immune checkpoint blockade: a common denominator approach to cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Cancer immunotherapy comes of age

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Oncology meets immunology: the cancer-immunity cycle

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Combination cancer immunotherapy and new immunomodulatory targets

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Engineered T cells: the promise and challenges of cancer immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

CANCER. The odds of immunotherapy success

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Genomic correlates of response to CTLA-4 blockade in metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Intracavitary Bacillus Calmette-Guerin in the treatment of superficial bladder tumors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Tumoricidal activity of TLR7/8-activated inflammatory dendritic cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Anti-viral activity induced by culturing lymphocytes with tumor-derived or virus-transformed cells. Enhancement of human natural killer cell activity by interferon and antagonistic inhibition of susceptibility of target cells to lysis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Imiquimod 5% cream for the treatment of actinic keratosis: results from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Topical TLR7 agonist imiquimod can induce immune-mediated rejection of skin metastases in patients with breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

First in human phase I trial of 852A, a novel systemic toll-like receptor 7 agonist, to activate innate immune responses in patients with advanced cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

A phase I dose-finding study of the novel Toll-like receptor 8 agonist VTX-2337 in adult subjects with advanced solid tumors or lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

STING is an endoplasmic reticulum adaptor that facilitates innate immune signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Direct Activation of STING in the Tumor Microenvironment Leads to Potent and Systemic Tumor Regression and Immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

RIG-I-like helicases induce immunogenic cell death of pancreatic cancer cells and sensitize tumors toward killing by CD8(+) T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

5'-Triphosphate-siRNA: turning gene silencing and Rig-I activation against melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

TLR4 signaling promotes immune escape of human lung cancer cells by inducing immunosuppressive cytokines and apoptosis resistance

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Cancer epigenetics: from mechanism to therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

How do tumor cells respond to HDAC inhibition?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Inhibitors of DNA Methylation, Histone Deacetylation, and Histone Demethylation: A Perfect Combination for Cancer Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Epigenetic modifiers in immunotherapy: a focus on checkpoint inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The anticancer effects of HDAC inhibitors require the immune system

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Class I histone deacetylase inhibition is a novel mechanism to target regulatory T cells in immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Limited gene activation in tumor and normal epithelial cells treated with the DNA methyltransferase inhibitor 5-aza-2'-deoxycytidine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Inhibition of DNA methyltransferase stimulates the expression of signal transducer and activator of transcription 1, 2, and 3 genes in colon tumor cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Decitabine Enhances Lymphocyte Migration and Function and Synergizes with CTLA-4 Blockade in a Murine Ovarian Cancer Model.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Inhibiting DNA Methylation Causes an Interferon Response in Cancer via dsRNA Including Endogenous Retroviruses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Endogenous retroviruses: acquisition, amplification and taming of genome invaders

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Immune responses to endogenous retroelements: taking the bad with the good

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Long Terminal Repeats: From Parasitic Elements to Building Blocks of the Transcriptional Regulatory Repertoire

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The Polycomb complex PRC2 and its mark in life

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

PRC2 Epigenetically Silences Th1-Type Chemokines to Suppress Effector T-Cell Trafficking in Colon Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

31 March 2020

Targeting EZH2 in cancer

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Global DNA hypomethylation coupled to repressive chromatin domain formation and gene silencing in breast cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Histone demethylation mediated by the nuclear amine oxidase homolog LSD1

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The histone demethylase KDM1A sustains the oncogenic potential of MLL-AF9 leukemia stem cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Inhibition of the LSD1 (KDM1A) demethylase reactivates the all-trans-retinoic acid differentiation pathway in acute myeloid leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The T-cell-receptor signaling network.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The Erk2 MAPK regulates CD8 T cell proliferation and survival

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

MEKK2 is required for T-cell receptor signals in JNK activation and interleukin-2 gene expression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The BRAF and MEK Inhibitors Dabrafenib and Trametinib: Effects on Immune Function and in Combination with Immunomodulatory Antibodies Targeting PD-1, PD-L1, and CTLA-4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

MAP Kinase Inhibition Promotes T Cell and Anti-tumor Activity in Combination with PD-L1 Checkpoint Blockade

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Hepatotoxicity with combination of vemurafenib and ipilimumab

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

All PI3Kinase signaling is not mTOR: dissecting mTOR-dependent and independent signaling pathways in T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Regulation of T cells by mTOR: the known knowns and the known unknowns

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Loss of PTEN Promotes Resistance to T Cell-Mediated Immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Cutting edge: the phosphoinositide 3-kinase p110 delta is critical for the function of CD4+CD25+Foxp3+ regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The PI3K p110δ regulates expression of CD38 on regulatory T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The p110delta isoform of phosphatidylinositol 3-kinase controls susceptibility to Leishmania major by regulating expansion and tissue homing of regulatory T cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Inactivation of PI(3)K p110δ breaks regulatory T-cell-mediated immune tolerance to cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Idelalisib and rituximab in relapsed chronic lymphocytic leukemia

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

PI3Kδ inhibition by idelalisib in patients with relapsed indolent lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

31 March 2020

TOR in the immune system

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

mTOR regulates memory CD8 T-cell differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Temsirolimus, an mTOR inhibitor, enhances anti-tumour effects of heat shock protein cancer vaccines

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

mTOR kinase inhibitor AZD8055 enhances the immunotherapeutic activity of an agonist CD40 antibody in cancer treatment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

An oscillatory switch in mTOR kinase activity sets regulatory T cell responsiveness.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Regulatory T cells require mammalian target of rapamycin signaling to maintain both homeostasis and alloantigen-driven proliferation in lymphocyte-replete mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

mTOR inhibition improves immune function in the elderly

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Promoting apoptosis as a strategy for cancer drug discovery

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

IAP inhibitors enhance co-stimulation to promote tumor immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

(Un)expected roles of c-IAPs in apoptotic and NFkappaB signaling pathways

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Inhibitor of apoptosis protein (IAP) antagonists demonstrate divergent immunomodulatory properties in human immune subsets with implications for combination therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Inhibitors of apoptosis proteins (IAPs) are required for effective T-cell expansion/survival during antiviral immunity in mice

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Tec family kinases in inflammation and disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Colocalization of X-linked agammaglobulinemia and X-linked immunodeficiency genes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Btk levels set the threshold for B-cell activation and negative selection of autoreactive B cells in mice.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Targeting Bruton's tyrosine kinase in B cell malignancies

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Altered T cell receptor signaling and disrupted T cell development in mice lacking Itk.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

T-cell signaling regulated by the Tec family kinase, Itk.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Impaired NFATc translocation and failure of Th2 development in Itk-deficient CD4+ T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Therapeutic antitumor immunity by checkpoint blockade is enhanced by ibrutinib, an inhibitor of both BTK and ITK

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Regulation of NF-κB-Dependent Lymphocyte Activation and Development by Paracaspase

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Bcl10 is a positive regulator of antigen receptor-induced activation of NF-kappaB and neural tube closure

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Differential Requirement for Malt1 in T and B Cell Antigen Receptor Signaling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

API2-MALT1 fusion protein induces transcriptional activation of the API2 gene through NF-kappaB binding elements: evidence for a positive feed-back loop pathway resulting in unremitting NF-kappaB activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Gain of chromosome region 18q21 including the MALT1 gene is associated with the activated B-cell-like gene expression subtype and increased BCL2 gene dosage and protein expression in diffuse large B-cell lymphoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Essential role of MALT1 protease activity in activated B cell-like diffuse large B-cell lymphoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

A loss-of-function RNA interference screen for molecular targets in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The proteolytic activity of the paracaspase MALT1 is key in T cell activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Cleavage of roquin and regnase-1 by the paracaspase MALT1 releases their cooperatively repressed targets to promote T(H)17 differentiation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The paracaspase MALT1 cleaves HOIL1 reducing linear ubiquitination by LUBAC to dampen lymphocyte NF-κB signalling

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Malt1-induced cleavage of regnase-1 in CD4(+) helper T cells regulates immune activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

T cell antigen receptor stimulation induces MALT1 paracaspase-mediated cleavage of the NF-kappaB inhibitor A20

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Th17 cells in cancer: the ultimate identity crisis.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Alternative splicing of MALT1 controls signalling and activation of CD4(+) T cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

MALT1 small molecule inhibitors specifically suppress ABC-DLBCL in vitro and in vivo

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Pharmacologic inhibition of MALT1 protease by phenothiazines as a therapeutic approach for the treatment of aggressive ABC-DLBCL.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Paracaspase MALT1 deficiency protects mice from autoimmune-mediated demyelination

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Malt1 protease inactivation efficiently dampens immune responses but causes spontaneous autoimmunity.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

MALT1 Protease Activity Is Required for Innate and Adaptive Immune Responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Deficiency of MALT1 paracaspase activity results in unbalanced regulatory and effector T and B cell responses leading to multiorgan inflammation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Combined immunodeficiency associated with homozygous MALT1 mutations

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Combined immunodeficiency due to MALT1 mutations, treated by hematopoietic cell transplantation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Immunological hallmarks of stromal cells in the tumour microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Genomic and Transcriptomic Features of Response to Anti-PD-1 Therapy in Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Microenvironmental regulation of metastasis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Co-evolution of tumor cells and their microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Hallmarks of Cancer: The Next Generation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Pathology: cancer cells compress intratumour vessels.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Normalization of tumor vasculature: an emerging concept in antiangiogenic therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Metabolic Competition in the Tumor Microenvironment Is a Driver of Cancer Progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Immunity, inflammation and cancer: a leading role for adenosine

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The development and immunosuppressive functions of CD4(+) CD25(+) FoxP3(+) regulatory T cells are under influence of the adenosine-A2A adenosine receptor pathway.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Targeting the hypoxia-adenosinergic signaling pathway to improve the adoptive immunotherapy of cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Antimetastatic effects of blocking PD-1 and the adenosine A2A receptor

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Adenosine Receptor 2A Blockade Increases the Efficacy of Anti-PD-1 through Enhanced Antitumor T-cell Responses

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Adenosine A2A receptors intrinsically regulate CD8+ T cells in the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

A Metabolic Immune Checkpoint: Adenosine in Tumor Microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

IDO expression by dendritic cells: tolerance and tryptophan catabolism

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Indoleamine 2,3-dioxygenase serves as a marker of poor prognosis in gene expression profiles of serous ovarian cancer cells

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Mechanism of tumor rejection with doublets of CTLA-4, PD-1/PD-L1, or IDO blockade involves restored IL-2 production and proliferation of CD8(+) T cells directly within the tumor microenvironment

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Macrophages and therapeutic resistance in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Breast cancer expression of CD163, a macrophage scavenger receptor, is related to early distant recurrence and reduced patient survival.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Possible involvement of the M2 anti-inflammatory macrophage phenotype in growth of human gliomas.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Indoleamine 2,3-dioxygenase is a critical resistance mechanism in antitumor T cell immunotherapy targeting CTLA-4.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

CSF-1R inhibition alters macrophage polarization and blocks glioma progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Targeting tumor-associated macrophages with anti-CSF-1R antibody reveals a strategy for cancer therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Targeting Suppressive Myeloid Cells Potentiates Checkpoint Inhibitors to Control Spontaneous Neuroblastoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The tumor microenvironment underlies acquired resistance to CSF-1R inhibition in gliomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Phase 2 study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 (CCL2), in metastatic castration-resistant prostate cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

A first-in-human, first-in-class, phase I study of carlumab (CNTO 888), a human monoclonal antibody against CC-chemokine ligand 2 in patients with solid tumors.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Carlumab, an anti-C-C chemokine ligand 2 monoclonal antibody, in combination with four chemotherapy regimens for the treatment of patients with solid tumors: an open-label, multicenter phase 1b study

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Cessation of CCL2 inhibition accelerates breast cancer metastasis by promoting angiogenesis

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

PI3Kγ is a molecular switch that controls immune suppression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Overcoming resistance to checkpoint blockade therapy by targeting PI3Kγ in myeloid cells.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Principles and mechanisms of vessel normalization for cancer and other angiogenic diseases

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Sorafenib reduces the percentage of tumour infiltrating regulatory T cells in renal cell carcinoma patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Sunitinib pretreatment improves tumor-infiltrating lymphocyte expansion by reduction in intratumoral content of myeloid-derived suppressor cells in human renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Combination immunotherapy with prostatic acid phosphatase pulsed antigen-presenting cells (provenge) plus bevacizumab in patients with serologic progression of prostate cancer after definitive local therapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Bevacizumab plus ipilimumab in patients with metastatic melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Beyond TGFβ: roles of other TGFβ superfamily members in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Targeting the TGFβ signalling pathway in disease

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Reversal of tumor-induced immunosuppression by TGF-beta inhibitors

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Phase I study of GC1008 (fresolimumab): a human anti-transforming growth factor-beta (TGFβ) monoclonal antibody in patients with advanced malignant melanoma or renal cell carcinoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

HGF rescues colorectal cancer cells from EGFR inhibition via MET activation

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Hepatocyte growth factor favors monocyte differentiation into regulatory interleukin (IL)-10++IL-12low/neg accessory cells with dendritic-cell features

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Chronic lymphocytic leukemia nurse-like cells express hepatocyte growth factor receptor (c-MET) and indoleamine 2,3-dioxygenase and display features of immunosuppressive type 2 skewed macrophages

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

β-catenin signaling controls metastasis in Braf-activated Pten-deficient melanomas

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Melanoma-Derived Wnt5a Promotes Local Dendritic-Cell Expression of IDO and Immunotolerance: Opportunities for Pharmacologic Enhancement of Immunotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Immunological Effects of Conventional Chemotherapy and Targeted Anticancer Agents

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Immunogenic Chemotherapy Sensitizes Tumors to Checkpoint Blockade Therapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Ipilimumab in combination with paclitaxel and carboplatin as first-line therapy in extensive-disease-small-cell lung cancer: results from a randomized, double-blind, multicenter phase 2 trial

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Immunosuppressive plasma cells impede T-cell-dependent immunogenic chemotherapy

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Carboplatin and pemetrexed with or without pembrolizumab for advanced, non-squamous non-small-cell lung cancer: a randomised, phase 2 cohort of the open-label KEYNOTE-021 study.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Immunotherapy and stereotactic ablative radiotherapy (ISABR): a curative approach?

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

An abscopal response to radiation and ipilimumab in a patient with metastatic non-small cell lung cancer.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

A systemic complete response of metastatic melanoma to local radiation and immunotherapy.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Immunologic correlates of the abscopal effect in a patient with melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Radiation and dual checkpoint blockade activate non-redundant immune mechanisms in cancer

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Pooled Analysis of Long-Term Survival Data From Phase II and Phase III Trials of Ipilimumab in Unresectable or Metastatic Melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

BRAF inhibition is associated with enhanced melanoma antigen expression and a more favorable tumor microenvironment in patients with metastatic melanoma.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Improved antitumor activity of immunotherapy with BRAF and MEK inhibitors in BRAF(V600E) melanoma

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

Immune regulation by low doses of the DNA methyltransferase inhibitor 5-azacitidine in common human epithelial cancers.

31 March 2020

1 reference

https://api.crossref.org/works/10.1038%2FNRC.2017.17

inferred from DOI database lookup

7 January 2021

based on heuristic

Identifiers

DOI

10.1038/NRC.2017.17

1 reference

9 September 2017

1 reference